Anti-angiogenic therapies based on targeted disruption of
Introduction
The ability of modulators of angiogenesis to enhance endothelial cell survival, or to induce endothelial cell apoptosis, plays an important role in vascular homeostasis. 1 An increasing number of pro-angiogenic molecules have been characterized as enhancers of endothelial cell survival. VEGF binding to its endothelial cellspecific receptor Flk-1/KDR, and engagement of the PI3 kinase-Akt and Bcl-2 signaling pathways, has been shown to protect endothelial cells against various apoptotic stimuli including growth factor deprivation. [2] [3] [4] The pro-angiogenic molecules angiopoietin-1, bFGF, and ␣ V ␤ 3 also mediate signaling cascades that result in enhanced survival of endothelial cells. [5] [6] [7] VEGF and the pro-angiogenic factors described above appear to function primarily at the level of newly formed vessels where they promote survival by repressing endothelial cell apoptosis. 1 There is mounting evidence that conditions that enhance endothelial cell survival contribute to the pathogenesis of angiogenesis-dependent diseases such as cancer, [8] [9] [10] psoriasis, 11, 12 retinopathy of prematurity, 13 and Crohn's disease.
14 Therefore, reduction or disruption of the local microvasculature associated with the growth and/or maintenance of pathological tissue could be beneficial for the treatment of these diseases. Several anti-angiogenic strategies have been proposed to limit pathological angiogenesis. Endogenous inhibitors of angiogenesis such as endostatin and interferon-␣, as well as drugs and antibodies that inhibit pro-angiogenic signaling pathways are presently in clinical trials for the treatment of solid tumors. 15 Most of these strategies are based on the blockade of upstream signaling events that are triggered at the level of the endothelial cell membrane. These anti-angiogenic approaches have shown efficacy by themselves or in combination with other therapeutic modalities for the inhibition of tumor growth in animal models. [15] [16] [17] The anti-angiogenic effect is mediated at least in part by the suppression of intracellular pro-survival molecules that act to repress the activation of apical caspases and apoptosis in endothelial cells. However, the engagement of parallel endothelial cell survival pathways may be sufficient to re-establish tissue vascularization and resistance to anti-angiogenic therapies. In this scenario, the use of approaches that directly target components of the cell death machinery might circumvent the mechanisms of resistance to antiangiogenic therapy. Because apoptotic stimuli often engage multiple intracellular pathways, it is unknown whether activation of apical caspases is sufficient to induce endothelial cell apoptosis and disruption of microvessels in vivo. In this report, we expressed iCaspase-9, a conditional caspase-9 molecule that is activated upon drug-induced dimerization, [18] [19] [20] [21] in primary endothelial cells and evaluated the effect of active iCaspase-9 in functional human microvessels engineered in immunodeficient mice.
Results

AP20187 induces activation of iCaspase-9 in microvascular endothelial cells
To assess the ability of caspase-9 to induce apoptosis in primary endothelial cells, we constructed a recombinant retrovirus that expresses a conditional allele of human procaspase-9 ( Figure 1a) . The modified procaspase-9 mol- 19, 22 We infected human dermal microvascular endothelial cells (HDMECs) with the iCaspase-9 retrovirus or control viruses and selected cell pools for a minimum of 2 weeks in the presence of G418. Immunoblotting with anti-caspase-9 antibody revealed that HDMECs transduced with the iCaspase-9 vector, but not with control retrovirus, expressed the chimeric iCaspase-9 protein (Figure 1b) . Importantly, the expression levels of iCaspase-9 were comparable to those of endogenous caspase-9 detected in both control virusinfected and uninfected HDMECs, or in human umbilical vein endothelial cells (HUVECs) (Figure 1b) . We also determined that the expression of Apaf-1, an adaptor molecule that oligomerizes and activates caspase-9 in the presence of cytochrome-c and dATP 23 was not significantly affected by the retroviral infection procedure (Figure 1b) .
To determine if the ectopically expressed iCaspase-9 can be activated by dimerization, we incubated two independently derived populations of HDMECs expressing inducible F V 2-Caspase-9 (HDMEC-iCasp-9) with the dimerizer drug AP20187. Immunoblotting of cell extracts with anti-HA antibody revealed the formation of processed caspase-9 corresponding to the large subunit of active iCaspase-9 in a drug-dependent manner ( Figure  1c ).
Activation of caspase-9 is sufficient to induce endothelial cell apoptosis
We next assessed whether drug-induced activation of caspase-9 can trigger apoptosis of HDMECs. By 48 h of treatment with the dimerizer drug there was significant apoptosis of HDMECs (Figure 2a) . By 96 h, up to 90% of the cells had undergone apoptosis whereas no significant apoptosis was observed in HDMECs transduced with control virus (Figure 2a) . Thus, the dimerizer drug AP20187 did not appear to be toxic to control HDMECs, in agreement with a report that described low or no cytotoxicity of the drug to other cell types. 22 As low as 0.01 nM of AP20187 induced significant apoptosis and the level of apoptosis plateaued with 1 nM of the drug (Figure 2b ). Under all conditions examined, induction of apoptosis in HDMECs was dependent on the addition of AP20187 and the expression of chimeric F v 2-caspase-9. Microscopic examination of the AP20187-treated HDMECs showed rounded and shrunken cells, whereas untreated cells or AP20187-treated control HDMEC-LXSN cells appeared healthy and remained attached to the tissue culture plate (Figure 2c -f).
Dimerization of iCaspase-9 induces activation of endogenous caspase-3 in HDMECs
To understand the mechanism of apoptosis mediated by activated caspase-9 in endothelial cells, we evaluated the ability of dimerized iCaspase-9 to activate endogenous caspase-3, a downstream target of active caspase-9. 24 As expected, treatment with AP20187 did not cause processing of endogenous caspase-3 in HDMECs transduced with control viruses (Figure 3a) . In contrast, HDMEC-
Figure 2 Induced dimerization of iCaspase-9 mediates apoptosis of human endothelial cells. (a, b) HDMECs transduced with iCaspase-9 or LXSN were exposed to 100 nM AP20187 for 0-96 h (a); or exposed to 0-100 nM AP20187 for 96 h (b). Apoptotic cells were identified by flow cytometry. Data represent mean values (± s.d.) of triplicate samples from three independent experiments. (c-f) Photomicrographs (at ×200) of representative fields depicting cells cultured in the presence or absence of AP20187 for 96 h.
iCasp-9 cells exposed to AP20187 for 48 h had a decrease in the endogenous level of the 32 kDa zymogen form that coincided with the appearance of a processed p17 fragment, the large subunit of active caspase-3 ( Figure 3a) . After 72 h, the p17 fragment disappeared presumably due to its further degradation in dying cells. To determine if AP20187 induces the enzymatic activation of caspase-3, we determined the ability of cell extracts prepared from HDMEC-iCasp-9 to cleave the fluorogenic Ac-DEVD-AMC substrate as a measurement of caspase-3 activation. We found that AP20187 induced caspase-3 activity in extracts from HDMEC-iCasp-9, but not in extracts prepared from untreated HDMECs or treated cells containing control virus (Figure 3b ). The caspase-3 enzymatic activity was completely blocked by the addition of Ac-DEVD-CHO to the lysates (Figure 3c ), demonstrating specificity of the enzymatic activity in these lysates.
VEGF or bFGF does not prevent apoptosis induced by caspase-9 in endothelial cells
Several approaches to target signaling pathways that are required for the survival of tumor-associated vasculature have been proposed. However, tumor cells often secrete multiple survival factors that may limit the efficacy of such anti-angiogenic strategy. We therefore tested if apoptosis and caspase activation induced by iCaspase-9 could be affected by VEGF and bFGF, two potent antiapoptotic factors for endothelial cells in newly formed vessels. [3] [4] [5] [6] In these experiments, we pre-incubated HDMEC-iCasp-9 with either VEGF or bFGF for 24 h, then added AP20187 and fresh VEGF or bFGF and measured the percentage of apoptotic cells after incubation with the dimerizer drug. Treatment of HDMEC-iCasp-9 with VEGF or bFGF did not have a significant effect on the levels of apoptosis triggered by induced dimerization of caspase-9 ( Figure 4a ). In addition, VEGF or bFGF did not prevent the processing of procaspase-9 (Figure 4b ).
Induced dimerization of caspase-9 in endothelial cells disrupts microvessels in vivo
Endothelial cells lining microvessels are interconnected and exposed to constant stimulation from the surrounding environment. Under physiological conditions, it is unknown whether activation of caspases in endothelial cells is sufficient to trigger apoptosis and disruption of microvessels. To test if activated caspase-9 is pro-apoptotic in vivo, we implanted biodegradable scaffolds seeded with HDMEC-iCasp-9 cells or control HDMECs. We have previously shown that HDMECs implanted subcutaneously in severe combined immunodeficient (SCID) mice organize into functional human microvessels that anastomose with the host vasculature and transport mouse blood cells. 3, 9, 25 After the establishment of human microvessels, we injected AP20187 intraperitoneally and evaluated the microvessel density in the implants. By 24 h, visual inspection revealed that implants containing HDMECs transduced with control virus were pink-red, whereas those containing HDMEC-iCasp-9 were pale (Figure 5a ), suggesting that caspase-9 dimerization induces diminution of blood flow to the implants. Microscopic evaluation of implants seeded with HDMECs transduced with control virus did not show significant change in microvascular density, whereas contralateral implants containing HDMEC-Casp-9 cells exhibited a dramatic reduction in microvessels (Figure 5b-f) . These findings indicate that the effect of AP20187 was specific to endothelial cells expressing chimeric iCaspase-9.
Dimerization of caspase-9 induces apoptosis in microvascular endothelial cells in vivo
We next assessed whether disruption of microvessels was associated with apoptosis of endothelial cells. Implants seeded with HDMEC-iCasp-9 or HDMEC-LXSN were labeled by the TUNEL assay to identify cells with fragmented DNA. We detected an increase in the number of microvessels containing TUNEL-positive endothelial cells 
HDMEC-iCasp-9(a) exposed to 0 (᭜) or 100 nM AP20187 (ᮀ); HDMEC-iCasp-9(b) exposed to 0 (᭺) or 100 nM AP20187 (̅); and 1 ng of purified recombinant human Caspase-3 (). (c) The specificity of caspase-3 activation was determined by the addition of the inhibitor Ac-DEVD-CHO to the reaction. Data represent mean values (± s.d.) of triplicate samples per condition.
in implants containing HDMEC-iCasp-9 cells 12 h after administration of the dimerizer, but not in control implants ( Figure 6 ). These results indicate that dimerization of caspase-9 caused apoptosis of endothelial cells resulting in the disruption of microvessels in vivo.
Discussion
Several strategies that target endothelial survival pathways have been proposed on the premise that angiogenesis-dependent diseases may regress if neovascularization is disrupted. 26, 27 In the case of cancer, it is thought that these strategies can potentially overcome acquired Gene Therapy drug resistance since the cellular targets of such therapies are normal, genetically stable microvascular endothelial cells. 15 However, because such approaches target specific signaling pathways, resistance to anti-angiogenic therapy may arise if tumor cells secrete multiple survival factors to maintain their own capillary network. These 'alternative' angiogenic factors may either override apoptotic signals mediated by 'direct-acting' anti-angiogenic drugs, or prevent endothelial cell apoptosis when survival pathways are blocked with inhibitors of survival signaling pathways. Here we used a conditional allele of caspase-9, iCaspase-9, and showed that activation of the caspase-9 pathway induces apoptosis of endothelial cells, even when these cells are treated with anti-apoptotic growth factors, such as VEGF or bFGF. Furthermore, activation of iCaspase-9 was sufficient to induce apoptosis of endothelial cells in vivo resulting in ablation of human microvessels in immunodeficient mice. These results are consistent with previous observations that showed that factors such as VEGF promote endothelial cell survival by acting on various molecules including Bcl-2 and Akt, [2] [3] [4] that are known to function upstream of caspase-9 in the apoptosis pathway. 24 Most anti-angiogenic strategies currently in clinical trials are based on the delivery of antibodies or drugs that inhibit endothelial cell-specific survival signals and promote apoptosis by a default mechanism. In these approaches, the therapeutic agents are inherently targeted to the endothelium, but most of these agents induce moderate levels of apoptosis. 28, 29 In contrast, approaches that directly target the cell death machinery might be more effective in inducing endothelial cell apoptosis and disrupting microvessels in vivo. Because the caspase-9 allele used in the present studies acts as a cellular artificial death switch (ADS) which is activated with dimerizer drugs, the construct used here or related caspase-based suicide switches 18, 21 could be activated in a controlled manner in tumors.
The inherent challenge of the strategy proposed here is that the components of the cell death machinery are expressed ubiquitously in mammalian cells. Therefore the use of these approaches for anti-angiogenic cancer therapy will require specific delivery of the suicide gene to the neovascular endothelial cells of the tumor vasculature. We are currently working on gene delivery vectors based on adenoviruses that express iCaspase-9 under the control of an endothelial cell specific promoter, [30] [31] [32] and that are retargeted to the endothelium by the use of an endothelial-specific ligand incorporated into the viral genome. [33] [34] [35] [36] The aim of this work is to characterize an adenoviral vector that will allow for the delivery of iCaspase-9 specifically to neovascular endothelial cells. The data presented here provide the evidence that justifies the search for such a vector, since it demonstrates unequivocally that once iCaspase-9 is expressed in neovascular endothelial cells, its activation by a cell-permeable dimerizer drug results in disruption of microvessels and a profound reduction in tissue microvascular density in vivo. Furthermore, we showed that the surrounding stromal cells that depend on the microvessel for nutrient input and survival also undergo apoptosis once this vessel was disrupted by activated iCaspase-9 (Figure 6d) .
In summary, we demonstrate here that dimerization of iCaspase-9 in endothelial cells is sufficient to disrupt functional human microvessels in vivo, resulting in localized decrease of microvascular density. The results suggest that an anti-angiogenic gene therapy approach based on the delivery and controlled activation of a caspase-based suicide gene in endothelial cells may be efficient in reducing tumor microvascular density. Therefore, here we provide a conceptual framework for the development and characterization of targeted adenoviral vectors with enhanced tropism to neovascular endothelium for the delivery and expression of iCaspase-9 in the tumor microvasculature. The activation of an inducible death gene in tumor endothelial cells alone, or in combination with the administration of specific inhibitors of angiogenesis, might enhance the effectiveness of anti-angiogenic cancer therapies by overcoming acquired resistance mediated by multiple upstream survival pathways.
Materials and methods
Retroviral constructs and HDMEC transduction
The generation of HDMEC-Casp-9 cells was performed as described. 3 Briefly, a 2-kb cassette containing HAtagged human F v 2-caspase-9, 21 now called iCaspase-9, was inserted into the HpaI cloning site of the retroviral vector LXSN (gift from AD Miller, Fred Hutchinson Cancer Research Center, Seattle, WA, USA). The iCaspase-9 construct, reverse orientation control, or vector alone was transfected into PA317 amphotropic packaging cells with Fugene 6 (Roche Molecular Biochemicals, Indianapolis, IN, USA) to generate recombinant retroviruses. HDMEC (Clonetics, San Diego, CA, USA) were transduced by three consecutive 4-h long incubations with 1/5 dilutions of the viral supernatant in endothelial cell growth medium (EGM2-MV; Clonetics) containing 4 g/ml polybrene. HDMEC transduced with iCaspase-9 or controls were selected for a minimum of 2 weeks in EGM2-MV containing 250 g/ml G418 (Invitrogen, Carlsbad, CA, USA). anti-HA (Santa Cruz, Santa Cruz, CA, USA). Blots were exposed to appropriate peroxidase-coupled secondary antibodies and protein expression was detected with ECL (Amersham, Arlington Heights, IL, USA). Membranes were reprobed with monoclonal mouse anti-GAPDH antibody (Chemicon, Temecula, CA, USA) to control for equal loading.
(b) Graph depicting the number of microvessels in implants populated with HDMEC-LXSN () or HDMEC-iCasp-9 (¼) retrieved from mice injected daily with 2 mg/kg AP20187. Data represent mean values (± s.d.) of 10 microscopic fields (at ×200) analyzed in five implants per cell type and time point. (c-f) Immunohistochemical staining for Factor VIII (positive cells are labeled in red) of implants populated with HDMEC-LXSN or HDMEC-iCasp-9. Representative microscopic fields (at ×200) of implants populated with HDMEC-LXSN (c) or HDMEC-iCasp-9 (d) from a control mouse that was not injected with AP20187; and implants populated with HDMEC-LXSN (e) or HDMEC-iCasp-9 (f) from a mouse killed 24 h after a single intraperitoneal injection of 2 mg/kg AP20187. Arrowheads depict representative
Flow cytometry HDMEC-Casp-9 or HDMEC-LXSN cells were exposed to 0-100 nM AP20187 (Ariad Pharmaceuticals, Cambridge, MA, USA) in EGM2-MV for 0-96 h. When indicated, 50 ng/ml VEGF 165 (Intergen, Purchase, NY, USA); 50 ng/ml bFGF (Invitrogen); or 10 ng/ml TNF-␣ (Collaborative Biomedical, Cambridge, MA, USA) and 5 g/ml cycloheximide (Sigma, St Louis, MO, USA) were added to the EGM2-MV 24 h before and during treatment with 100 nM AP20187. Cells were retrieved, washed and incubated in 50 g/ml propidium iodide, 0.1% sodium citrate, 0.1% Triton, 100 g/ml RNAse for 30 min. Apoptotic cells were quantified by flow cytometry (EPICS; Beckman Coulter, Miami, FL, USA).
Fluorometric assay of Caspase-3 activity
The ability of dimerized iCaspase-9 to activate endogenous caspase-3 was determined in cell extracts as described. 37, 38 The reactions were carried out at 37°C with 10 M Ac-DEVD-AMC (Alexis, San Diego, CA, USA). DEVDase activity was examined with a luminescence fluorometer (Cytofluor 2300; Millipore, Bedford, MA, USA). Purified recombinant human caspase-3 was used as posiotive control, and Ac-DEVD-CHO (Alexis) was used to examine non-specific caspase-3 activity. 38 
SCID mouse model of human angiogenesis
The effect of activated endothelial cell caspase-9 in implant microvascular density was examined by seeding 1 × 10 6 HDMEC-iCasp-9 or HDMEC-LXSN in poly-(Llactic acid) (PLLA; Medisorb, Cincinnati, OH, USA) biodegradable scaffolds that were implanted into SCID mice (CB.17.SCID; Taconic, Germantown, NY, USA) as described. 3, 25 Two sponges seeded with HDMEC-iCasp-9 and two with HDMEC-LXSN were implanted subcutaneously in the dorsum of each mouse. All mice were killed 21 days after implantation, and implants were fixed in 10% buffered formalin at 4°C. Before death, the animals included in the 12-24-h experimental time-points received a single intraperitoneal injection of 2 mg/kg AP20187 (Ariad) in a solution of 10% PEG 400 and 1.7% Tween 20. The animals included in the 2-5-day time periods received daily injections of AP20187, as described above. The care and treatment of mice were in accordance with University of Michigan's institutional guidelines.
Immunolocalization of microvessels and in situ TUNEL assay Microvessels were identified by incubating tissue sections with polyclonal rabbit anti human Factor VIII antibody (Lab Vision, Freemont, CA, USA), or with monoclonal mouse anti human CD34 (Lab Vision). 3, 25 The number of stained microvessels was counted blindly in 10 random fields per implant at ×200. Five implants from independent mice were evaluated per time-point and cell type. TUNEL staining (ApopTag peroxidase in situ detection kit; Intergen) was used according to the manufacturer's instructions. 3, 9 Statistical analysis Statistical significance was determined at the P Ͻ 0.05 level, using one-way ANOVA and the Student-NewmanKeuls test.
